BEIJING: The first and currently the only special medical zone in China, the Boao Lecheng International Medical Tourism Pilot Zone in Qionghai, Hainan province, which provides world-class medical tourism services to domestic and international patients, has experienced a rapid increase in visitors.
In the first two months of this year, the number of visitors to Lecheng was 34,651, a year-on-year growth of 37.2 percent, and the combined number of patients licensed to use medical devices and drugs was 1,546, representing an annual growth of 58.40 percent. The pilot zone was established with the approval of the State Council in 2013 and has been granted a number of preferential policies.
“Lecheng is able to make use of medical devices and drugs licensed abroad but not yet in China, providing patients with advanced international-standard diagnosis and treatment,” said Yan Lukai, publicity director of the zone’s administration.
The pilot zone has set up an independent regulatory regime for devices and drugs that manages approval, customs clearance, use and supervision.
With approval, companies can obtain special licenses to use first-in-class drugs and equipment, permitting patients to benefit from innovative global pharmaceuticals and medical devices. The zone has a unique supervision platform capable of tracking the process of importing medical devices. It has a simplified approval policy that adopts online approval, and a shortened processing time from 27 days to under a week.
A bonded warehouse for imported medications has also been built to facilitate imports.
“We have introduced measures to permit specially approved drugs to be taken out of the pilot zone, which means that patients no longer have to be hospitalized here each time they need to make use of the drugs in question,” Yan said. “Under the measures, patients are permitted to take a small amount of oral medications for urgent clinical and personal needs out of Lecheng.”
The zone has introduced some 300 urgently needed medical devices and drugs, and become the most important pathway for innovative international medical products to enter the Chinese market. It has also established relations with nearly 80 pharmaceutical device and drug manufacturers in 18 countries, and cooperates extensively with the top 30 international companies in the field, the administration said.
–The Daily Mail-China Daily news exchange item
